AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie is acquiring Waltham-based biotech firm Apogee Therapeutics in a deal valued at $10.9 billion to bolster its immunology drug portfolio.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AbbVie has reached an agreement to acquire Apogee Therapeutics. The transaction is valued at $10.9 billion and centers on the acquisition of the company's long-acting immunology and inflammation drug candidates.
Coverage from Reuters, Endpoints News, the Financial Times, NBC Boston, and Yahoo Finance highlights the focus on immunology. Reports identify the target as a Waltham-based biotech company, with financial outlets tracking the deal's impact on broader sector valuations.
Market observers are now evaluating the landscape for additional biotech takeover targets. Further updates regarding the integration process or regulatory steps have not yet been specified in the coverage.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5h ago.
Quick answers
What is the value of the deal?
The acquisition is valued at $10.9 billion.
What is the primary focus of the acquisition?
The deal targets Apogee Therapeutics' long-acting immunology and inflammation drug candidates.
Where is the acquired company located?
Apogee Therapeutics is based in Waltham.
Coverage (6)
- AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidates Endpoints News · 2d ago
- AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports Reuters · 2d ago
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 2d ago
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal Yahoo Finance · 2d ago
- AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics Financial Times · 2d ago
- AbbVie sharpens immunology focus with $10.9 billion Apogee deal Reuters · 2d ago
Topics
Related trends
Bob Iger Says Disney Held Talks With Apple About a Deal But They “Didn’t Show That Much Interest”
Former Disney CEO Bob Iger reveals a history of ambitious, unsuccessful acquisition talks with major technology and entertainment firms.
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s lung cancer drug fails pivotal trial, sending shockwaves through biotech markets
ROBERT F. KENNEDY JR.: The future of medicine should be built in America
Debate intensifies over U.S. and China biotechnology competition as industry leaders and officials weigh the risks of domestic dependence and trade restrictions.
HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials
U.S. overhauls clinical trials to reclaim global biotech dominance amid China’s rise
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
AbbVie’s $10.9B bid for Apogee Therapeutics signals a high-stakes bet on next-gen autoimmune treatments—including a rival to Dupixent.